In-Vivo Imaging of Microscopic Residual Disease in Cancer [BPN685]
Successful treatment of early stage cancer depends on the ability to resect both gross and microscopic disease. Microscopic residual disease (MRD) can lead to increased risk for local recurrence (LR) and reduced overall survival (OS). Currently, no methods exist to intraoperatively assess whether individual cancer cells remain in the tumor bed; only post-operative pathologic evaluation of the tumor for molecular tumor markers, requiring several days in a laboratory setting, can definitely identify MRD. A prime example of this occurs in the over 50,000 women each year who are diagnosed with breast cancer, and are found to have MRD after lumpectomy. Elimination of MRD in breast cancer is known to reduce the need for second surgical procedures, half the LR rate from 30% to 15%, and increase breast cancer survival. Therefore a method of imaging MRD intraoperatively to guide complete resection is essential. This projects seeks to develop a method for intraoperatively identifying microscopic residual disease.